FIELD: pharmacology.
SUBSTANCE: compounds can be used to prepare a medicament for treatment or prevention of a disease selected from the group consisting of organ transplant rejection, graft versus host transplantation, autoimmune disease, allergic diseases and chronic myeloproliferative disease. The disease can be selected from rheumatoid arthritis, psoriasis, atopic dermatitis or a disease caused by dry eyes. In the general formula
Ra is the same or different and each represents (1) C1-6 alkyl or (2) a halogen atom, n1 is an integer selected from the integers from 0 to 2, Rb are the same or different and each represents (1) C1-6 alkyl or (2) halogen atom, n2 is an integer selected from the integers from 0 to 2, m1 is an integer selected from the integers from 0 to 3, m2 is an integer selected from the integers from 1 to 4, Xa=Xb is (1) CH=CH, (2) N=CH or (3) CH=N, X is (1) a nitrogen atom or (2) C-Rd, where Rd is a hydrogen atom or halogen atom, Rc is a group selected from the following groups (1)-(6): (1) a hydrogen atom, (2) C1-6 alkyl, optionally substituted with 1-5 same or different substituents selected from the following group A, (3) -C(=O)-Rc1, (4) -C(=O)-O-Rc2, (5) -C(=O)-NRc3Rc4, where Rc1, Rc2, Rc3, Rc4 are the same or different and each represents (i) a hydrogen atom or (ii) C1-6 alkyl, optionally substituted with 1-5 same or different substituents selected from the following group A, or (6) a group of the following formula
in which Ya is a group selected from the following groups (i) to(iii) (i) C1-6 alkylene, (ii) -C(=O)- or (iii) -S(=O)-O-, ring T is (i) a phenyl, (ii) C3-10 cycloalkyl or (iii) a saturated monoheterocyclyl, which contains 1 nitrogen atom and carbon atoms, and the number of atoms, constituting the ring, is 3-7, Rc5 is the same or different and each represents (i) cyano, or (ii) a nitro group, p is an integer selected from the integers from 0 to 1, group A is a group, consisting of (a) a hydroxyl, (b) C1-6 alkoxy, (c) a cyano, (d) C1-6 alkoxycarbonyl, (e) C1-6 alkylcarboxylic and (f) C2-6 alkenylacyl.
EFFECT: increased efficiency of treatment.
60 cl, 33 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
ETHYLENEDIAMINE DERIVATIVES AND FXa INHIBITOR AND ANTICOAGULANT COMPRISING THEREOF | 2001 |
|
RU2268259C2 |
GUANIDINE DERIVATIVES, METHOD OF PREPARATION THEREOF, AND METHOD FOR INHIBITING Na/H EXCHANGE IN CELLS | 1994 |
|
RU2141946C1 |
RETINOID-LIKE COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | 1996 |
|
RU2163590C2 |
INHIBITOR OF INTEGRIN EXPRESSION | 2001 |
|
RU2240826C2 |
NOVEL COUMARIN DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | 2007 |
|
RU2428420C2 |
DERIVATIVES OF BENZOPYRANE-2-ONE, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND INTERMEDIATE COMPOUNDS | 1997 |
|
RU2194052C2 |
SULPHONYLUREAS AND RELATED COMPOUNDS AND THEIR USE | 2016 |
|
RU2795512C2 |
NEW BIPHENYL COMPOUND OR ITS SALT | 2016 |
|
RU2726622C2 |
SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | 2011 |
|
RU2652638C2 |
SULFONYL UREA AND RELATED COMPOUNDS AND USE THEREOF | 2016 |
|
RU2739356C2 |
Authors
Dates
2017-09-12—Published
2010-07-30—Filed